Colorectal cancer represents the second most common cause of cancer-related death. The human A33 transmembrane glycoprotein is a validated tumor-associated antigen, expressed in 95% of primary and metastatic colorectal cancers. Using phage display technology, we generated a human monoclonal antibody (termed A2) specific to A33 and we compared its epitope and performance to those of previously described clinical-stage anti-human A33 antibodies. All antibodies recognized a similar immunodominant epitope, located in the Vdomain of A33, as revealed by SPOT-analysis. The A2 antibody homogenously stained samples of poorly, moderately and well-differentiated colon adenocarcinomas. All antibodies also exhibited an intense staining of healthy human colon sections. The A2 antibody, reformatted in murine IgG2a format, preferentially localized to A33-transfected CT26 murine colon adenocarcinomas in immunocompetent mice with a homogenous distribution within the tumor mass, while other antibodies exhibited a patchy uptake in neoplastic lesions. A2 efficiently induced killing of A33-expressing cells through antibody-dependent cell-mediated cytotoxicity in vitro and was able to inhibit the growth of A33-positive murine CT26 and C51 lung metastases in vivo. Anti-A33 antibodies may thus represent useful vehicles for the selective delivery of bioactive payloads to colorectal cancer, or may be used in IgG format in settings of minimal residual disease.
INTRODUCTION
Colorectal cancer (CRC) is one of the most common cancer types worldwide and ranks second in terms of cancer-related deaths [1] . Approximately 20% of newly diagnosed CRC patients have already developed metastases in the liver, lungs, lymph nodes, peritoneum or soft tissues [2] . Despite significant progresses in standard care of therapies, including antibody-based therapeutics inhibiting angiogenesis (anti-VEGF-A) or tumor growth factors (anti-EGFR), the prognosis of patients with metastatic CRC remains poor [3] . Immune checkpoint inhibitors, which provide a clinical benefit for patients with many different types of malignancies, are typically not active for the treatment of colorectal cancer [4] , exception made for DNA Mismatch Repair-Deficient or Microsatellite Instability-High metastatic CRC patients, which respond positively to the combination treatment of nivolumab (anti-PD-1) and ipilimumab (anti-CTLA-4) [5] . For these reasons, there is an urgent need to develop more efficacious strategies for the treatment of patients with metastatic CRC.
Intense research efforts are currently being devoted to the implementation of antibody-based therapeutic strategies, in which the antibody moiety serves as delivery vehicle for bioactive agents. Radionuclides [6] , immunostimulatory cytokines [7, 8] and T cell engagers (e.g., bispecific antibodies; [9] ) have been considered as payloads for the treatment of metastatic CRC. In this context, the carcinoembryonic antigen (CEA) and transmembrane glycoprotein A33 represent the most commonly used target antigens, which have received extensive Nuclear Medicine validation in patients, using radiolabeled preparations of monoclonal antibody reagents [6, [10] [11] [12] [13] .
A33 is expressed in epithelia of the lower gastrointestinal tract and in 95% of primary and metastatic colorectal cancers [14] . Clinical-stage antibodies have been developed against A33 and have been used for CRC treatment either as "naked" immunoglobulins [15] , engineered for the delivery of beta-emitting radionuclides [6] or of T cell-engaging antibody moieties [16] . The first anti-A33 antibody to be used for tumor-targeting application was developed by the group of Lloyd J. Old [17] . In this article, it will be referred to as "K". A humanized version of K (here described as K.hu) was reported in 1995 [18] . Recently, MacroGenics has described the isolation and characterization of a novel humanized monoclonal antibody (here described as "MG"), which has been used for the development of bispecific products in DART ® format [16] .
Here we describe the isolation and characterization of a novel human antibody (termed A2), specific to A33. A2, which was compared to the K, K.hu and MG antibodies in terms of biochemical properties and tumor-targeting characteristics, was found to avidly bind to CRC specimens in vitro and in vivo. The novel anti-A33 antibody was able to kill A33-expressing murine adenocarcinoma cells by ADCC in vitro and prevent formation of murine CRC lung metastases in vivo. The results described in this article suggest that A2 may be applied as intact antibody able to kill colorectal tumor cells through ADCC, or as building block for the implementation of antibody-based therapeutic strategies for the treatment of metastatic CRC.
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RESULTS
Murine model of colorectal cancer expressing human A33
The human transmembrane glycoprotein A33 is expressed in 95% of human colorectal cancers but has only 67% amino acid identity with its murine counterpart. In order to establish an immunocompetent murine model of colorectal cancer expressing A33, we stablytransfected the murine colorectal carcinoma cell lines CT26 wt and C51 wt with the gene coding for A33 [ Figure 1a ]. The resulting clones CT26 A33.C3 and C51 A33.A5 , selected by antibiotic resistance and single-cell sorting, showed a shift in fluorescence intensity upon FACS analysis using A33-specific antibodies, compared to isotype controls [ Figure 1a ]. The staining intensities were comparable with the one observed using the LS174T cells human colorectal cancer cell line.
Expression of recombinant A33-His and antibody isolation
The extracellular Ig-like domains of A33 were cloned with a His-tag at the C-terminus into the mammalian expression vector pcDNA3.1(+) for protein expression in CHO cells [ Figure   1a ]. The purified recombinant glycoprotein A33-His eluted as a single peak in size exclusion chromatography and migrated as a large band in non-reducing SDS-PAGE analysis, revealing a higher molecular weight (Mw) than the calculated Mw of 24.4 kDa. The sequence of A33 [ Supplementary Figure 1 ] contains three possible sites for N-linked glycosylation.
Deglycosylation of A33-His with PNGase led to the formation of a smaller and uniform band, with apparent Mw of 30kDa in SDS-PAGE analysis [Figure 1a ]. 6 
Isolation of an A33 specific monoclonal antibody by phage display
The human antibody A2 in scFv format was isolated by panning the ETH-2-Gold phage display library [19] against A33-His, immobilized on a solid support. ScFv(A2) was reformatted into a chimeric murine IgG2a format for mammalian cell expression [ Figure 1b ].
Figure 1c
indicates the amino acid sequence of scFv(A2), highlighting the portions of the CDR3 loops of V H and V L domains that had been combinatorially mutated in the ETH-2-Gold library.
Expression and characterization of anti-A33 antibodies in the IgG2a format
In order to compare the antibody A2 to previously described clinical-stage anti-A33 antibodies [K [17] , K.hu [18] and MG [9] ], all antibodies were reformatted in murine IgG2a format. The proteins were expressed in CHO cells and purified to homogeneity, using Protein Figure   4a ]. The stronger functional affinity of K and K.hu to A33 on CT26 A33.C3 cells compared to A2 and MG, does not match with the BIAcore profiles on the immobilized A33. TA99, specific to a melanoma antigen [20] , was used as negative control of irrelevant specificity in 7 this context.
Characterization of binding epitopes by SPOT technology
In order to identify the binding site of the anti-A33 antibodies, we used SPOT technology [21] and immunodetection of antibody binding events to 15 amino acid long peptides on a cellulose membrane, spanning the antigen sequence. All three antibodies (A2, K and MG) recognized an immunodominant site of the A33 antigen [ Figure 3b ,c]. At a four times higher concentration, K and MG antibodies (2 µg/ml) generated multiple signals on the A33 peptide membrane, possibly indicating discontinuous binding epitopes on the Ig-like V-type (red) and
Ig-like C2-type (green) domains [ Figure 3b ,c]. The TA99 antibody, serving as negative control of irrelevant specificity in this setting, did not exhibit binging on the SPOT assay [ Figure 3c ].
Comparison of A33 detection on human tissues
The A2, K and MG antibodies were studied by immunofluorescence staining on a tissue array, which contained 37 colorectal cancer sections and 3 normal colon sections. The three antibodies were used at identical concentrations for the immunofluorescence analysis, while the TA99 antibody was used as negative control [ Supplementary Figure 3 ]. Figure 4 shows sections stained in green with individual anti-A33 antibodies, while the vasculature was stained in red with an anti-Von Willebrand Factor reagent. The A2 antibody exhibited a brighter and more homogenous staining of tissue sections, compared to the K and MG antibodies, regardless of the tumor differentiation status [Figure 4 ]. A complete analysis of the tissue arrays can be found in Supplementary Figure 3 .
In vivo biodistribution of anti-A33 antibodies
The tumor-homing properties of the anti-A33 antibodies were assessed in immunocompetent BALB/c mice, bearing subcutaneously-grafted CT26 A33.C3 carcinomas. An ex vivo immunofluorescence analysis, performed 24 hours after intravenous administration of A2, K and MG respectively, revealed a selective homing of the antibodies to the tumor cells [ Figure   5 ]. By contrast, the negative control antibody TA99 did not exhibit any detectable accumulation at the tumor site at the same time point. A2 exhibited a more homogeneous and less patchy distribution within the tumor mass, compared to the K and MG counterparts.
In vitro and in vivo A2-mediated cytotoxicity against C51 A33.C3 and CT26 A33.C3 colorectal cell lines
The anti-A33 antibody A2 was reformatted into human IgG1, in order to test its ability to induce ADCC in vitro, using human peripheral blood mononuclear cells (PBMCs). The sequence of IgG1(A2) and the protein characterization is reported in Supplementary Figure   4 . The target cell lines C51 A33.C3 and CT26 A33.C3 were stained with 5(6)-Carboxyfluorescein diacetate N-succinimidyl ester (CFSE) dye and incubated with different concentrations of IgG1(A2) and human PMBCs, at 1:50 ratio. IgG1(KSF), directed against hen egg lysozyme
[22] was used as negative control in this setting. Flow cytometric analyses after 24 hours incubation revealed a specific and concentration-dependent depletion of CFSE-labeled target cells by the IgG1(A2) antibody [ Figure 6a ]. In vivo, the A2 antibody was used in the 9 chimeric murine IgG2a format, in a setting aimed at preventing lung metastases. IgG2a(A2) was administered immediately after the intravenous injection of C51 A33.C3 or CT26 A33.C3 murine adenocarcinoma cells into BALB/c mice. The treatment significantly inhibited lung metastasis formation in both CT26 and C51 models, compared to saline or isotype-matched negative control antibodies (p < 0.05 for C51 A33.C3 against isotype control and saline, p < 0.01 for CT26 A33.C3 against isotype control and p < 0.001 against saline) [Figure 6b ]. 10 
DISCUSSION
We have reported the generation of a novel fully-human antibody specific to the human tumor-associated antigen A33. The antibody, named A2, was compared in vitro and in vivo with two previously described anti-A33 antibodies, called K [17] and MG [9, 16] .
The murine antibody K was tested in the early 90's in Phase I/II clinical trials, in which the product was used as "delivery vehicle" for 131 I [23] or 125 I [24] in patients with metastatic CRC. A humanized version of the K antibody (referred to as K.hu), with longer serum halflife, was also used for radioimmunotherapy in radioiodinated form. The product did not induce objective tumor responses I patients, but a high accumulation in CRC metastases could be detected using Nuclear Medicine techniques [25] . Gastrointestinal toxicity was not reported, in spite of the fact that labeled K.hu antibody was found to also localize to the normal gastrointestinal tract [26] . After repeated monthly administrations, the humanized K.hu antibody induced a human anti-human antibody (HAHA) response in the majority of CRC patients (73%) [15] , as evidenced by BIAcore analysis of sera. These data suggest that a less immunogenic anti-A33 antibody may be required for future clinical projects.
The ADCC represents an elegant avenue for re-directing the cytotoxic potential of immune effector cells to malignant cells, expressing a target antigen. We and others have previously shown that the main limitation for an efficient implementation of ADCC in a solid tumor setting relates to the lack of active immune effector cells in the neoplastic mass [27] . Clinical applications of monoclonal antibodies inducing ADCC for the treatment of disseminated solid tumors have been unsuccessful in most cases [28, 29] . However, the use of Trastuzumab as adjuvant treatment in metastatic breast cancer was shown to provide a substantial benefit to patients [30] , suggesting that ADCC strategies may be better suited for the treatment of minimal residual disease. The good tolerability of intact antibodies make them suitable for adjuvant therapy, when long term treatment is required. Alternatively, ADCC activity in solid tumors may be boosted by combination therapies with tumor-targeted immunostimulatory cytokines [27, 31, 32] .
A33 expression in human CRC has been described to be heterogeneous [33, 34] , as also observed by immunofluorescent staining of human CRC tissue sample [ Supplementary   Figure 3 ]. Therapeutic strategies capable of inducing a bystander effect on antigen-negative cells [35] [36] [37] may be particularly suited when targeting the A33 antigen.
The novel anti-A33 A2 antibody was able to successfully deliver payloads to the tumor site and to inhibit cancer dissemination in a minimal residual disease setting. A2 in IgG format may therefore be considered for adjuvant treatment applications in CRC patients or as a versatile "vehicle" for the delivery of bioactive payloads.
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MATERIALS AND METHODS
Cell lines
CHO cells, the murine colorectal carcinoma cell line CT26 wt and the human colorectal cell lines HT-29 and LS174T were obtained from the ATCC between 2015 and 2017, expanded, and stored as cryopreserved aliquots in liquid nitrogen. Cells were grown according to the manufacturer's protocol. Transfected CT26 cells were kept in the same culture conditions as CT26.wt cells.
Cloning, expression, biotinylation and characterization of the antigen
The cDNA encoding for the A33 construct was obtained by total RNA extraction from the HT-29 colorectal carcinoma cell line (High Pure RNA Isolation Kit, Roche), reverse transcription (Transcriptor reverse transcriptase, Roche) and amplification of A33 cDNA by Taq DNA Polymerase (Sigma-Aldrich). The extracellular domains of the antigen were PCR amplified, extended with a nucleic acid sequence encoding for 6 histidine residues (His-tag) and cloned into the mammalian expression vector pcDNA3.1(+) (Invitrogen). The soluble antigen was produced by transient gene expression in CHO cells as described previously [38] and purified from the cell culture medium by Ni-NTA resin (Roche). Quality control of A33-His was performed by SDS-PAGE and size exclusion chromatography (Superdex75 10/300GL, GE Healthcare). The protein was digested with PNGase F (New England BioLabs) under denaturating conditions. A33-His was biotinylated with Sulfo-NHS-LC-Biotin (Pierce). Biotinylation of the antigen was tested through Mass Spectrometry (MS) analysis and band shift assay [ Supplementary Figure 5 ].
Transfection of human A33 in CT26 tumor cells and monoclonal selection
The gene for human A33 was cloned into the mammalian expression vector pcDNA3.1(+) containing an antibiotic resistance for G418 Geneticin. The plasmid was digested with PvuI (HF) for linearization prior to transfection. CT26 wt and C51 wt cells were transfected with the A33 gene in pcDNA3.1(+) using the Amaxa™ 4D-Nucleofector (Lonza) and the SG Cell Line 4D-Nucleofector® X Kit L (Lonza) and reseeded. Three days after the transfection, the growing medium was supplemented with 0.5 mg/ml G418 (Merck) for selection of stably transfected polyclonal cells. To obtain a monoclonal cell line, single cell sorting of stable transfected cells was performed using BD FACSAria III. Different clones were expanded and checked for antigen expression by FACS analysis and immunofluorescence. Clones CT26 A33.C3 and C51 A33.A5 were selected as the best clone based on A33 surface expression and cell viability.
Selection of A33.A2 from the ETH-2-Gold library by phage display
The recombinant biotinylated A33-His antigen was immobilized on streptavidin (StreptaWells, Roche) or avidin coated wells (Avidin, Sigma-Aldrich on MaxiSorp plates, Sigma). Monoclonal antibodies were isolated from the synthetic human scFv antibody library ETH-2-Gold [19] by two rounds of biopanning as previously described [39, 40] . Supernatants of single bacterial colonies expressing the selected scFvs were screened by ELISA on 15 immobilized A33-His. Clones yielding positive ELISA signals were sequenced and binding to the cognate antigen was confirmed by FACS analysis on the human colorectal carcinoma cell line LS174T and the transfected murine colorectal carcinoma cell line CT26 A33.C3 .
Cloning, expression and characterization of the anti-A33 antibodies
Sequences of the variable region of the light and heavy chain (V H and V L ) of A33.K and A33.K.hu were taken from King D.J., et. al [18] . Sequences of A33.MG V H and V L were found in the patent file from MacroGenics [9] . The genes encoding for V H and V L of the antibodies A2, K, K.hu and MG, and the constant regions of the IgG2a immunoglobulin were PCR amplified, PCR assembled, and cloned into the mammalian expression vector pMM137, as previously described [27] . The IgG2a molecules were produced using transient gene expression in CHO cells following standard protocols [22, 38] and purified from the cell culture medium to homogeneity by Protein A chromatography (Thermo Scientific). Quality control of the proteins was performed by SDS-PAGE and size exclusion chromatography (Superdex200 10/300GL, GE Healthcare). The full amino acid sequences are presented in Supplementary Figure 2 . The A2 antibody was additionally expressed in the human IgG1 format, for testing ADCC activity with human PBMCs. The sequence and characterization of IgG1(A2) are reported in Supplementary Figure 4 . Flow cytometry CT26 wt , CT26 A33.C3 , C51 wt , C51 A33.A5 and LS174T cells were detached with 2mM EDTA from the culture flask and stained with the different concentrations (75-0.001µg/ml) of the respective anti-A33 antibody or the negative control TA99. The antibodies were detected using donkey anti-mouse Alexafluor488 (Invitrogen). All staining and washing steps were performed in 2 mM EDTA 0.5% BSA in PBS. Cells were sorted by FACS (CytoFLEX, Beckman Coulter) and analyzed using FlowJo software.
Surface plasmon resonance analysis on A33-his coated chip
Epitope mapping using peptide array
The binding epitope of the anti-A33 antibodies on the A33 extracellular domain was determined using a peptide array (PepSpot, JPT). Sequences of 15 amino acid long peptides covering the whole sequence of the A33 extracellular domain with overlapping linear sequences were covalently bound to a cellulose membrane on 51 different spots. The assay was performed according to manufacturer's instructions and the binding spots were detected by a chemiluminescence imager (Agfa Curix 60, Agfa Healthcare). The respective IgG2a antibodies were incubated with the PepSpot membrane at concentrations ranging from 0.5 µg/ml to 2µg/ml and detected by protein A-HRP (GE Healthcare).
Ex-vivo immunofluorescences on CT26 A33.C3 tumor bearing mice
7 weeks old BALB/c mice were obtained from Janvier. 4x10 6 . CT26 A33.C3 cells were injected subcutaneously (s.c.) in the left flank of each mouse. The anti-A33 antibodies A2, K and MG were labelled with fluorescein isothiocyanate (FITC) as described in the manufacturer's protocol (Sigma). For ex vivo immunofluorescence analysis, BALB/c mice bearing CT26 A33.C3 s.c. tumors (100mm 3 ) were injected with 150µg FITC-labelled IgG2a antibody.
Mice were sacrificed 24 hours after injection. The organs were excised, embedded in cryoembedding medium (Thermo Scientific) and cryostat sections (8 mm) were stained using rabbit anti-FITC (BioRad; 4510-780) and rat anti-CD31 (BD Biosciences; 553370) as primary antibody and donkey anti-rabbit Alexa488 (Invitrogen; A21206) and anti-rat Alexa594 (Invitrogen; A21209) as secondary antibodies. Slides were mounted with fluorescent mounting medium (Dako) and analyzed with Axioscop2 mot plus microscope (Zeiss). In vivo experiments were performed under project licenses issued by the Veterinäramt des Kantons Zürich, Switzerland (Bew. Nr. 04/18).
Immunofluorescence analysis on human colorectal tumor sections
Arrays of freshly frozen human colorectal tumor (37) and healthy colon tissues (3) were obtained from Amsbio. A list of the 40 different tissues, including pathology grade is shown in Supplementary Figure 3 . For immunofluorescence analysis the tissue arrays were fixed in chilled acetone before staining. As primary staining antibodies A2, K, MG and TA99 were used at a concentration of 1µg/ml together with a rabbit anti-human Von Willebrand Factor (1:800, Dako) in 3% BSA in PBS. Detection was performed using a donkey anti-mouse IgG Alexafluor 488 (Invitrogen, A21202) and goat anti-rabbit IgG (Invitrogen, A11037).
In vitro ADCC assay on CT26 A33.C3 and C51 A33.A5 cells CT26 A33.C3 and C51 A33.A5 were stained with CFSE dye (BioLegend) as described by the manufacturer's protocol and seeded in a 48-well plate (2⋅10 4 /well). Peripheral blood samples were obtained from healthy donors from the Blutspendedienst SRK, Zurich. PBMCs were isolated by density gradient centrifugation on Ficoll Paque Plus (GE Healthcare) following the manufacturer's protocol. The peripheral blood was diluted 1:3 in 2 mM EDTA / PBS. 30 ml of diluted peripheral blood were layered on 12.9 ml Ficoll and centrifuged at 400g for 40 min at RT. PBMCs were collected, washed twice with PBS/EDTA and incubated with the tumor target cells (10 6 /well, 1:50 target:effector ratio) in CT26 A33.C3 and C51 A33.A5 culture media. The antibody IgG1(A2) was added at different concentrations to the wells (total volume of 200µl/well) and the plate was incubated at 37°C, 5% CO 2 for 24 hours. On the next day, the samples with IgG1(A2) + PBMCs + target cells were transferred to a 96-well plate, washed twice with PBS and stained Fixable Viability Dye (Invitrogen) for 30 min. The samples were washed twice with 2 mM EDTA 0.5% BSA in PBS, before being analyzed by FACS (CytoFLEX, Beckman Coulter). The percentage of living target cells was derived from the mean fluorescence intensity of the CFSE positive cell population normalized based on the negative control samples containing PBMCs and target cells only.
In vivo prevention of CT26 A33.C3 and C51 A33.A5 lung metastases formation 5⋅10 5 CT26 A33.C3 or 5⋅10 4 C51 A33.A5 cells were injected intravenously through the tail vein of 7 weeks old BALB/c mice (Janvier). Mice were injected with saline, 200µg of A2 or TA99 antibody in the IgG2a format as indicated in Figure 7b (black arrows). After euthanasia, 19 mice were perfused with 1% PFA through the pulmonary artery and the aorta after. Lungs were excised and fixed for 1h in 4% PFA. Lung metastases were excised and weighted.
Unresectable, visible metastases were counted and added to the final weight (1mg each). Blood vessels stained with an anti-Von Willebrand Factor antibody (red, Alexa fluor 595). 30 Each horizontal line represents sequential sections from the same tumor sample, stained with a different antibody. Tumor samples vary in degree of differentiation. Scale bar = 150µm. 
